ELAN RSI Chart
Last 7 days
1.2%
Last 30 days
28.3%
Last 90 days
5.9%
Trailing 12 Months
97.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 4.4B | 0 | 0 | 0 |
2023 | 4.4B | 4.3B | 4.4B | 4.4B |
2022 | 4.7B | 4.6B | 4.5B | 4.4B |
2021 | 3.9B | 4.6B | 4.8B | 4.8B |
2020 | 3.0B | 2.8B | 2.9B | 3.3B |
2019 | 3.1B | 3.1B | 3.1B | 3.1B |
2018 | 2.9B | 3.0B | 3.0B | 3.1B |
2017 | 2.9B | 2.9B | 2.9B | 2.9B |
2016 | 0 | 0 | 0 | 2.9B |
2015 | 0 | 0 | 0 | 2.9B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 03, 2024 | bettington timothy j | sold (taxes) | -363,484 | 15.43 | -23,557 | see remarks |
Apr 01, 2024 | modi rajeev a. | sold (taxes) | -119,919 | 15.97 | -7,509 | see remarks |
Mar 08, 2024 | doyle william f | bought | 244,500 | 16.3 | 15,000 | - |
Mar 08, 2024 | harrington michael j | bought | 50,493 | 16.2883 | 3,100 | - |
Mar 06, 2024 | hoover r david | bought | 322,808 | 16.1404 | 20,000 | - |
Mar 05, 2024 | young todd s. | gifted | - | - | 1,500 | see remarks |
Mar 05, 2024 | young todd s. | gifted | - | - | -37,999 | see remarks |
Mar 05, 2024 | simmons jeffrey n | sold (taxes) | -176,082 | 15.99 | -11,012 | president, ceo and director |
Mar 05, 2024 | young todd s. | gifted | - | - | 37,999 | see remarks |
Which funds bought or sold ELAN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Global Financial Private Client, LLC | new | - | 71,913 | 71,913 | 0.03% |
May 16, 2024 | COMERICA BANK | added | 272 | 143,890 | 190,736 | -% |
May 16, 2024 | Ancora Advisors LLC | added | 1.37 | 16,820,400 | 173,239,000 | 3.94% |
May 16, 2024 | INNEALTA CAPITAL, LLC | sold off | -100 | -208,764 | - | -% |
May 16, 2024 | Tidal Investments LLC | added | 34.55 | 117,529 | 367,521 | 0.01% |
May 16, 2024 | Redwood Investment Management, LLC | new | - | 1,512,000 | 1,512,000 | 0.14% |
May 16, 2024 | Beacon Capital Management, LLC | unchanged | - | 882 | 2,849 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -78.07 | -2,457,580 | 774,423 | -% |
May 16, 2024 | Creekmur Asset Management LLC | unchanged | - | 1,158 | 13,659 | -% |
May 16, 2024 | Colony Group, LLC | new | - | 186,000 | 186,000 | -% |
Unveiling Elanco Animal Health Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Elanco Animal Health Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Elanco Animal Health Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 16.4% | 1,205 | 1,035 | 1,068 | 1,057 | 1,257 | 985 | 1,026 | 1,175 | 1,226 | 1,112 | 1,131 | 1,278 | 1,243 | 1,140 | 890 | 586 | 658 | 787 | 771 | 782 | 731 |
Costs and Expenses | 2.7% | 1,193 | 1,162 | 2,165 | 1,136 | 1,149 | 1,074 | 1,070 | 1,189 | 1,151 | 1,237 | 1,261 | 1,515 | 1,322 | 1,460 | 1,099 | 663 | 726 | 792 | 784 | 731 | 686 |
S&GA Expenses | 15.4% | 337 | 292 | 313 | 353 | 327 | 302 | 298 | 343 | 323 | 327 | 342 | 385 | 349 | 374 | 278 | 163 | 182 | 186 | 192 | 201 | 181 |
R&D Expenses | 10.1% | 87.00 | 79.00 | 86.00 | 81.00 | 81.00 | 80.00 | 78.00 | 82.00 | 81.00 | 92.00 | 94.00 | 94.00 | 89.00 | 115 | 88.00 | 59.00 | 67.00 | 67.00 | 70.00 | 69.00 | 64.00 |
EBITDA Margin | -46.8% | -0.07* | -0.05* | -0.04* | 0.19* | 0.20* | 0.19* | 0.18* | 0.16* | 0.11* | 0.08* | 0.05* | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | -1.5% | 66.00 | 67.00 | 72.00 | 74.00 | 64.00 | 62.00 | 60.00 | 67.00 | 52.00 | 55.00 | 60.00 | 60.00 | 61.00 | 60.00 | 48.00 | 25.00 | 16.00 | 19.00 | 19.00 | 21.00 | 21.00 |
Income Taxes | -242.9% | -20.00 | 14.00 | -1.00 | 18.00 | 5.00 | -35.00 | 21.00 | -4.00 | 24.00 | -15.00 | -22.00 | -37.00 | -13.00 | 5.00 | -74.00 | -24.00 | -19.00 | 5.00 | -22.50 | 14.00 | 13.00 |
Earnings Before Taxes | 109.4% | 12.00 | -127 | -1,097 | -79.00 | 108 | -89.00 | -44.00 | -14.00 | 75.00 | -120 | -130 | -243 | -77.00 | -318 | -209 | -77.00 | -68.00 | -4.30 | -12.50 | 50.00 | 45.00 |
EBT Margin | -9.3% | -0.30* | -0.27* | -0.26* | -0.02* | -0.01* | -0.02* | -0.02* | -0.04* | -0.09* | -0.12* | -0.16* | - | - | - | - | - | - | - | - | - | - |
Net Income | 122.7% | 32.00 | -141 | -1,096 | -97.00 | 103 | -54.00 | -65.00 | -10.00 | 51.00 | -105 | -108 | -206 | -64.00 | -322 | -135 | -53.00 | -49.00 | -9.50 | 10.00 | 36.00 | 32.00 |
Net Income Margin | -7.0% | -0.30* | -0.28* | -0.26* | -0.03* | -0.01* | -0.02* | -0.03* | -0.04* | -0.08* | -0.10* | -0.15* | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -Infinity% | -22.00 | - | 178 | 41.00 | -165 | -87.00 | 163 | 286 | -81.00 | 124 | 64.00 | 132 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.4% | 14,019 | 14,362 | 14,344 | 15,796 | 15,769 | 15,491 | 14,948 | 15,601 | 16,251 | 16,478 | 16,565 | 16,833 | 16,988 | 17,693 | 17,237 | 9,876 | 9,727 | 8,986 | 8,824 | 8,857 | 8,747 |
Current Assets | 18.9% | 4,050 | 3,407 | 3,565 | 3,652 | 3,548 | 3,279 | 3,154 | 3,307 | 3,194 | 3,274 | 3,160 | 3,431 | 3,344 | 3,417 | 3,281 | 3,191 | 3,121 | 2,373 | 2,310 | 2,384 | 2,278 |
Cash Equivalents | -2.0% | 345 | 352 | 369 | 367 | 318 | 345 | 460 | 507 | 342 | 638 | 453 | 580 | 515 | 506 | 660 | 1,391 | 1,206 | 345 | 309 | 385 | 272 |
Inventory | -5.6% | 1,638 | 1,735 | 1,690 | 1,690 | 1,596 | 1,538 | 1,340 | 1,334 | 1,345 | 1,371 | 1,383 | 1,450 | 1,424 | 1,578 | 1,597 | 1,065 | 1,019 | 1,051 | 1,069 | 1,053 | 1,036 |
Net PPE | -7.5% | 949 | 1,026 | 992 | 1,007 | 1,000 | 999 | 936 | 961 | 987 | 1,055 | 1,041 | 1,033 | 1,271 | 1,316 | 1,243 | 924 | 930 | 955 | 912 | 931 | 930 |
Goodwill | -12.1% | 4,478 | 5,094 | 4,902 | 6,040 | 6,061 | 5,993 | 5,716 | 5,898 | 6,116 | 6,172 | 6,191 | 6,239 | 6,016 | 6,225 | 6,435 | 3,044 | 3,004 | 2,990 | 2,946 | 2,960 | - |
Liabilities | -2.2% | 7,963 | 8,139 | 8,210 | 8,376 | 8,289 | 8,202 | 8,203 | 8,348 | 8,639 | 8,970 | 8,883 | 8,853 | 8,981 | 9,217 | 8,893 | 3,224 | 3,066 | 3,439 | 3,336 | 3,591 | 3,551 |
Current Liabilities | -0.7% | 1,232 | 1,241 | 1,265 | 1,284 | 1,578 | 1,702 | 1,613 | 1,338 | 1,307 | 1,647 | 1,362 | 1,990 | 2,034 | 2,077 | 1,871 | 835 | 708 | 819 | 742 | 778 | 708 |
Long Term Debt | -0.2% | 5,727 | 5,736 | 5,870 | 6,023 | 5,639 | 5,448 | 5,507 | 6,007 | 6,073 | 6,025 | 6,273 | 5,542 | 5,556 | 5,572 | 5,587 | 2,030 | 2,036 | 2,331 | 2,336 | 2,382 | 2,437 |
LT Debt, Current | 0% | 38.00 | 38.00 | 39.00 | 39.00 | 381 | 388 | 394 | 56.00 | 61.00 | 294 | 61.00 | 555 | 605 | 555 | 554 | 26.00 | 26.00 | 25.00 | 25.00 | 27.00 | 29.00 |
LT Debt, Non Current | -100.0% | - | 5,736 | 5,870 | 6,023 | 5,639 | 5,448 | 5,507 | 6,007 | 6,073 | 6,025 | 6,273 | 5,542 | 5,556 | 5,572 | 5,587 | 2,030 | 2,036 | 2,331 | 2,336 | 2,382 | 2,437 |
Shareholder's Equity | -2.7% | 6,056 | 6,223 | 6,134 | 7,420 | 7,480 | 7,289 | 6,714 | 7,125 | 7,585 | 7,508 | 7,682 | 7,980 | 8,007 | 8,457 | 8,344 | 6,652 | 6,661 | 5,543 | 5,488 | 5,266 | 5,196 |
Retained Earnings | 1.4% | -2,256 | -2,288 | -2,147 | -1,051 | -954 | -1,057 | -972 | -923 | -901 | -979 | -852 | -748 | -538 | -477 | -154 | -19.40 | 34.00 | 84.00 | 94.00 | 84.00 | 48.00 |
Additional Paid-In Capital | 0% | 8,777 | 8,777 | 8,763 | 8,752 | 8,744 | 8,738 | 8,724 | 8,712 | 8,699 | 8,696 | 8,680 | 8,663 | 8,647 | 8,650 | 8,620 | 6,886 | 6,870 | 5,636 | 5,646 | 5,397 | 5,399 |
Accumulated Depreciation | - | - | - | - | - | 744 | 723 | 696 | 688 | 670 | 1,041 | 1,050 | 1,054 | 1,060 | 1,038 | 983 | 942 | 920 | 931 | 909 | 921 | 909 |
Shares Outstanding | 0.2% | 494 | 493 | 493 | 493 | 492 | 474 | 488 | 488 | 488 | 487 | 487 | 487 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 4,900 | - | - | - | 9,300 | - | - | - | 16,400 | - | - | - | 8,600 | - | - | - | 12,400 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -98.7% | 2.00 | 157 | 198 | 61.00 | -145 | 13.00 | 189 | 312 | -62.00 | 223 | 89.00 | 149 | 22.00 | -93.00 | -112 | 160 | 4.00 | 126 | 40.00 | 50.00 | 8.00 |
Share Based Compensation | -26.7% | 11.00 | 15.00 | 10.00 | 9.00 | 12.00 | 15.00 | 13.00 | 17.00 | 14.00 | 18.00 | 17.00 | 16.00 | 15.00 | 16.00 | 12.00 | 8.00 | 11.00 | 12.00 | 15.00 | 14.00 | 8.00 |
Cashflow From Investing | 205.7% | 37.00 | -35.00 | -36.00 | -43.00 | -55.00 | -76.00 | -37.00 | -37.00 | -29.00 | -74.00 | -441 | -25.00 | 10.00 | -74.00 | -4,696 | 11.00 | -20.00 | -74.50 | -83.00 | -46.50 | -31.00 |
Cashflow From Financing | 80.6% | -27.00 | -139 | -157 | 39.00 | 174 | -84.00 | -169 | -96.00 | -200 | 44.00 | 231 | -67.00 | 2.00 | -18.00 | 4,068 | 7.00 | 897 | -6.40 | -48.80 | 90.00 | -339 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 1,205 | $ 1,257 |
Costs, expenses and other: | ||
Cost of sales | 515 | 494 |
Research and development | 87 | 81 |
Marketing, selling and administrative | 337 | 327 |
Amortization of intangible assets | 133 | 134 |
Asset impairment, restructuring and other special charges | 46 | 40 |
Interest expense, net of capitalized interest | 66 | 64 |
Other expense, net | 9 | 9 |
Costs, expenses and other | 1,193 | 1,149 |
Income before income taxes | 12 | 108 |
Income tax (benefit) expense | (20) | 5 |
Net income | $ 32 | $ 103 |
Earnings per share: | ||
Basic (usd per share) | $ 0.06 | $ 0.21 |
Diluted (usd per share) | $ 0.06 | $ 0.21 |
Weighted-average shares outstanding: | ||
Basic (in shares) | 493.2 | 491.1 |
Diluted (in shares) | 496.0 | 492.8 |
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 345 | $ 352 |
Accounts receivable, net | 988 | 842 |
Other receivables | 90 | 168 |
Inventories | 1,638 | 1,735 |
Prepaid expenses and other | 338 | 310 |
Assets held for sale | 651 | 0 |
Total current assets | 4,050 | 3,407 |
Noncurrent Assets | ||
Goodwill | 4,478 | 5,094 |
Other intangibles, net | 4,196 | 4,494 |
Other noncurrent assets | 346 | 341 |
Property and equipment, net | 949 | 1,026 |
Total assets | 14,019 | 14,362 |
Current Liabilities | ||
Accounts payable | 302 | 270 |
Sales rebates and discounts | 318 | 367 |
Current portion of long-term debt | 38 | 38 |
Other current liabilities | 574 | 566 |
Total current liabilities | 1,232 | 1,241 |
Noncurrent Liabilities | ||
Long-term debt | 5,727 | 5,736 |
Deferred taxes | 530 | 567 |
Other noncurrent liabilities | 474 | 595 |
Total liabilities | 7,963 | 8,139 |
Commitments and Contingencies | ||
Equity | ||
Common stock, no par value, 5,000,000,000 shares authorized, 494,049,915 and 492,845,216 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Additional paid-in capital | 8,777 | 8,777 |
Accumulated deficit | (2,256) | (2,288) |
Accumulated other comprehensive loss | (465) | (266) |
Total equity | 6,056 | 6,223 |
Total liabilities and equity | $ 14,019 | $ 14,362 |
 | Mr. Jeffrey N. Simmons |
---|---|
 | elanco.com |
 | Pharmaceuticals |
 | 9000 |